Drug Profile

Research programme: RNAi therapeutics - Boehringer Ingelheim/Dicerna Pharmaceuticals

Alternative Names: DCR-LIV1

Latest Information Update: 05 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dicerna Pharmaceuticals
Developer Boehringer Ingelheim; Dicerna Pharmaceuticals
Class Amino sugars; Antihyperlipidaemics; Drug conjugates; Hepatoprotectants; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Jan 2024 RNAi therapeutics is still in research phase for Non-alcoholic steatohepatitis in Germany
03 Jan 2024 Boehringer Ingelheim, Ribocure Pharmaceuticals, and Suzhou Ribo Life Science entered in to a R&D agreement to develop RNAi therapeutics
28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com